Clik here to view.
ゲノミクス企業のルーセンスがCOVID-19診断／監視向けウイルス試料採取メディカルデバイスを開発
シンガポール （ビジネスワイヤ） — 分子診断企業のルーセンスは本日、SAFER-Sample（Stabilization of nucleic Acid Formulation for Evaluation of RNA、RNA評価向け核酸調製の安定化）キットの開発を発表しました。これはCOVID-19などのウイルス感染検査のし易さを向上させる試料採取メディカルデバイスです。...
View ArticleClik here to view.
住友重机械工业株式会社获得在日本生产和销售基于加速器的BNCT系统和照射剂量计算程序的医疗器械审批许可
东京 (美国商业资讯)–住友重机械工业株式会社(Sumitomo Heavy Industries, Ltd., TOKYO:6302)（总经理：下村真司，以下简称“SHI”）与STELLA PHARMA...
View ArticleClik here to view.
Samsung Bioepis Announces FDA Approval of 420 mg Multi-dose Vial of...
INCHEON, Korea Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved a 420 mg multi-dose vial of ONTRUZANT® (trastuzumab-dttb), a biosimilar...
View ArticleClik here to view.
IASO Biotherapeutics Raises $60 Million in Series B Financing Led by GL...
NANJING, China IASO Biotherapeutics (IASO BIO) today announced the completion of $60 million in series B financing led by GL Ventures, which is a venture capital fund of Hillhouse Capital focusing...
View ArticleClik here to view.
Laekna Acquires Exclusive Global Rights to Clinical-Stage Cancer Asset
SHANGHAI Laekna Therapeutics Shanghai Co., Ltd. (Laekna) today announced a new agreement with Novartis giving the China-based biotech company exclusive global rights to Novartis’ anti-PD-L1 Antibody...
View ArticleClik here to view.
基因组学公司路胜生物开发用于新冠病毒诊断和监测的采样器
新加坡 (美国商业资讯)–分子诊断公司路胜生物(Lucence)今天宣布成功开发了SAFER-Sample（Stabilization of nucleic Acid Formulation for Evaluation of RNA，用于评估RNA的核酸制剂稳定性）试剂盒，该试剂盒是一款旨在提高病毒（例如新冠病毒COVID19）感染检测可及性的采样医疗器械。...
View ArticleClik here to view.
NTHU’s Boron Neutron Capture Therapy Center Begins Treating Overseas Brain...
HSINCHU, Taiwan On February 14th the melodious strains of the fourth movement of Mahler’s Fifth Symphony were heard inside the building of Tsing Hua Open pool Reactor (THOR) at National Tsing Hua...
View ArticleClik here to view.
ENHERTU® Approved in Japan for Treatment of Patients with HER2 Positive...
TOKYO & MUNICH & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the approval of ENHERTU® (trastuzumab deruxtecan), a HER2 directed antibody...
View ArticleClik here to view.
CG Oncology Announces License and Commercialization Agreement with Kissei...
IRVINE, Calif. CG Oncology, Inc. has announced today an exclusive license, development and commercialization agreement with Kissei Pharmaceutical Co., Ltd. (“Kissei”) for its oncolytic immunotherapy...
View ArticleClik here to view.
Daiichi Sankyo Submits Application for CAR T Therapy Axicabtagene Ciloleucel...
TOKYO & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has submitted a New Drug Application (NDA) to Japan’s Ministry of Health, Labour...
View ArticleClik here to view.
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) in...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products...
View ArticleClik here to view.
武田薬品：エグゼクティブ報酬返還ポリシー（クローバックポリシー）の導入について
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社 (東証:4502) (NYSE:TAK)：...
View ArticleClik here to view.
Takeda Adopts Executive Compensation Recoupment Policy
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced that its Board of Directors approved an executive compensation recoupment policy (“clawback...
View ArticleClik here to view.
武田采用高管薪酬追回政策
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TOKYO:4502/NYSE:TAK)（“武田”）今天宣布，其董事会批准了一项高管薪酬追回政策（“追回政策”）。该追回政策的采纳是武田为进一步加强其一流公司治理承诺所作不懈努力的一部分，并且与武田的同业一致。...
View ArticleClik here to view.
武田ADCETRIS® (brentuximab...
马萨诸塞州剑桥和日本大阪 (美国商业资讯)– 武田药品工业株式会社(TSE:4502/NYSE:TAK)（“武田”）今天宣布，欧洲药品管理局(EMA)人用药品委员会(CHMP)对ADCETRIS® (brentuximab...
View ArticleClik here to view.
武田薬品、未治療の全身性未分化大細胞リンパ腫成人患者を治療するためのアドセトリス（ブレンツキシマブ・ベドチン）とCHP（シクロホスファミド+ドキソルビシン...
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） —...
View ArticleClik here to view.
European Commission Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) extended the current marketing authorization of...
View ArticleClik here to view.
Cullgen Announces Publication of Small Molecule BRAF Protein Degraders in...
SAN DIEGO Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today announced...
View ArticleClik here to view.
PharmaCyte Biotech Enters into License Agreement for COVID-19 Diagnostic Kits
LAGUNA HILLS, Calif. PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation...
View ArticleClik here to view.
欧盟委员会核准武田ALUNBRIG® (brigatinib)用于ALK+ NSCLC一线治疗
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited) (TSE:4502/NYSE:TAK)今天宣布，欧盟委员会(EC)扩大了ALUNBRIG...
View Article